{"id":"gemcitabine-s-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hand-foot syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis. S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and incorporates into DNA/RNA, enhancing the cytotoxic effects when combined with gemcitabine. This combination leverages complementary mechanisms to improve efficacy in solid tumors.","oneSentence":"Gemcitabine and S-1 are cytotoxic chemotherapy agents that work synergistically to inhibit DNA synthesis and cell division in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:23.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer"},{"name":"Biliary tract cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":"Advanced Biliary Tract Carcinoma","enrollment":30},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":"Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":102},{"nctId":"NCT05026905","phase":"PHASE2","title":"A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-12-28","conditions":"Phase II, Open-label, Parallel 2-arm, Multi-center","enrollment":66},{"nctId":"NCT03443492","phase":"PHASE2","title":"SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-03-26","conditions":"Locally Advanced or Metastatic Pancreatic Cancer","enrollment":130},{"nctId":"NCT06730009","phase":"PHASE1, PHASE2","title":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","status":"RECRUITING","sponsor":"Medigen Biotechnology Corporation","startDate":"2024-10-21","conditions":"Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable","enrollment":42},{"nctId":"NCT06584227","phase":"PHASE2","title":"Adebrelimab and Chidamide for Pancreatic Cancer","status":"RECRUITING","sponsor":"Liu Xiufeng","startDate":"2024-09-10","conditions":"Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT01878617","phase":"PHASE2","title":"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-23","conditions":"Medulloblastoma","enrollment":660},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT04172402","phase":"PHASE2","title":"NGS as the First-line Treatment in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2019-12-27","conditions":"Advanced Biliary Tract Cancer","enrollment":48},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT03406299","phase":"PHASE2","title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-19","conditions":"Biliary Tract Neoplasms","enrollment":92},{"nctId":"NCT06921252","phase":"","title":"Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?","status":"COMPLETED","sponsor":"Kochi University","startDate":"2010-01-01","conditions":"Pancreatic Cancer Metastatic","enrollment":276},{"nctId":"NCT06903273","phase":"PHASE2","title":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Biliary Tract Cancer (BTC)","enrollment":35},{"nctId":"NCT06809374","phase":"","title":"Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Kochi University","startDate":"2015-01-01","conditions":"Pancreatic Cancer Resectable","enrollment":100},{"nctId":"NCT06789679","phase":"PHASE2","title":"Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-25","conditions":"Pancreatic Adenocarcinoma","enrollment":128},{"nctId":"NCT05218889","phase":"PHASE1, PHASE2","title":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2021-08-04","conditions":"Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer","enrollment":90},{"nctId":"NCT00652054","phase":"PHASE2","title":"Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2005-06","conditions":"Metastatic Pancreatic Cancer","enrollment":39},{"nctId":"NCT06571461","phase":"PHASE3","title":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-09","conditions":"Pancreatic Cancer","enrollment":408},{"nctId":"NCT06422156","phase":"PHASE2","title":"SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-06-01","conditions":"Advanced Pancreatic Cancer","enrollment":73},{"nctId":"NCT05048524","phase":"PHASE2","title":"Peri-operative SLOG for Localized Pancreatic Cancer","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-09-03","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreas Cancer","enrollment":64},{"nctId":"NCT06229496","phase":"PHASE1","title":"Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":70},{"nctId":"NCT03796429","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-12-17","conditions":"Biliary Tract Cancer","enrollment":50},{"nctId":"NCT03777462","phase":"PHASE2","title":"Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":150},{"nctId":"NCT04373928","phase":"NA","title":"Personalized Precision Diagnosis and Treatment of Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2017-11-10","conditions":"Pancreatic Cancer","enrollment":100},{"nctId":"NCT05822453","phase":"PHASE2","title":"Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-04-30","conditions":"Biliary Tract Carcinoma","enrollment":20},{"nctId":"NCT05028439","phase":"NA","title":"RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma","status":"COMPLETED","sponsor":"First People's Hospital of Hangzhou","startDate":"2020-01-01","conditions":"Cholangiocarcinoma","enrollment":70},{"nctId":"NCT03559348","phase":"PHASE2","title":"Locally Advanced or Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-03","conditions":"Pancreatic Adenocarcinoma","enrollment":49},{"nctId":"NCT05268692","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","status":"RECRUITING","sponsor":"Kochi University","startDate":"2019-01-01","conditions":"Pancreatic Adenocarcinoma","enrollment":500},{"nctId":"NCT02131493","phase":"PHASE2","title":"S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2015-01","conditions":"Pancreatic Cancer","enrollment":80},{"nctId":"NCT05138159","phase":"PHASE2","title":"A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12-01","conditions":"Metastatic Pancreatic Cancer","enrollment":10},{"nctId":"NCT03051373","phase":"PHASE2","title":"Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2017-04-01","conditions":"Carcinoma, Transitional Cell","enrollment":108},{"nctId":"NCT03986294","phase":"PHASE2","title":"Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-12-01","conditions":"Metastatic Pancreatic Cancer","enrollment":122},{"nctId":"NCT00429858","phase":"PHASE2","title":"Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Andrew Ko","startDate":"2007-01-22","conditions":"Pancreatic Cancer","enrollment":21},{"nctId":"NCT04377048","phase":"PHASE2","title":"Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-07-01","conditions":"Stage IV Pancreatic Cancer","enrollment":38},{"nctId":"NCT04319471","phase":"PHASE2","title":"Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":70},{"nctId":"NCT03869294","phase":"","title":"GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2014-01-01","conditions":"Pancreatic Cancer, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":96},{"nctId":"NCT04101929","phase":"PHASE2","title":"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-10-01","conditions":"Metastatic Pancreatic Cancer","enrollment":126},{"nctId":"NCT02425137","phase":"PHASE2","title":"A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2015-04","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":51},{"nctId":"NCT03779464","phase":"PHASE2","title":"Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-08-01","conditions":"Pancreatic Cancer, Nab-paclitaxel, Gemcitabine","enrollment":132},{"nctId":"NCT02182778","phase":"PHASE3","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2014-07-09","conditions":"Biliary Tract Cancer","enrollment":246},{"nctId":"NCT01821248","phase":"PHASE2","title":"A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis","status":"UNKNOWN","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-07-23","conditions":"Biliary Tract Cancer","enrollment":25},{"nctId":"NCT03825328","phase":"PHASE2","title":"A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )","status":"UNKNOWN","sponsor":"Yanqiao Zhang","startDate":"2019-01-30","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT03398291","phase":"PHASE3","title":"Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-07-01","conditions":"Pancreatic Cancer, Liver Metastases, Surgery","enrollment":300},{"nctId":"NCT03636308","phase":"PHASE2","title":"Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Peking University","startDate":"2018-07-17","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT02558868","phase":"PHASE2","title":"Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2015-09-01","conditions":"Pancreatic Neoplasms","enrollment":80},{"nctId":"NCT01815307","phase":"PHASE2","title":"Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-01","conditions":"Biliary Tract Cancer","enrollment":70},{"nctId":"NCT01929421","phase":"PHASE2","title":"A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2009-12","conditions":"Advanced Colorectal Cancer","enrollment":36},{"nctId":"NCT01430052","phase":"PHASE2","title":"Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Osaka Medical Center for Cancer and Cardiovascular Diseases","startDate":"2009-04","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT01713387","phase":"PHASE1","title":"A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2012-04","conditions":"Biliary Tract Cancer","enrollment":38},{"nctId":"NCT03278015","phase":"PHASE2","title":"Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-10-01","conditions":"Cancer of Pancreas","enrollment":90},{"nctId":"NCT01693419","phase":"PHASE2","title":"S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2011-08","conditions":"Pancreas Neoplasms","enrollment":37},{"nctId":"NCT02734680","phase":"NA","title":"IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2016-02","conditions":"Pancreatic Cancer","enrollment":70},{"nctId":"NCT01946646","phase":"PHASE1","title":"Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2013-10","conditions":"Metastatic Pancreatic Cancer","enrollment":10},{"nctId":"NCT02878889","phase":"PHASE2","title":"A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-08","conditions":"Nasopharyngeal Carcinoma","enrollment":53},{"nctId":"NCT03009253","phase":"NA","title":"Translational Research on Locally Advanced Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2015-07","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT02981641","phase":"NA","title":"IORT Versus CCRT for Pancreatic Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2015-12","conditions":"Pancreatic Cancer Stage IV","enrollment":100},{"nctId":"NCT00602745","phase":"PHASE3","title":"S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-02","conditions":"Pancreatic Neoplasm, Neoplasm Metastasis","enrollment":61},{"nctId":"NCT01415713","phase":"PHASE1, PHASE2","title":"The Study of Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2012-03","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":73},{"nctId":"NCT01291615","phase":"PHASE1","title":"Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":6},{"nctId":"NCT01284413","phase":"PHASE1, PHASE2","title":"Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":68},{"nctId":"NCT02146703","phase":"PHASE2","title":"Gemcitabine and S-1 for Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2005-08","conditions":"Biliary Tract Neoplasm","enrollment":38},{"nctId":"NCT01074996","phase":"PHASE2","title":"Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers","status":"UNKNOWN","sponsor":"The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","startDate":"2010-02","conditions":"Pancreatic Cancer","enrollment":92},{"nctId":"NCT01375972","phase":"PHASE2","title":"Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-03","conditions":"Metastatic Biliary Cancer","enrollment":92},{"nctId":"NCT00514163","phase":"PHASE2","title":"GEM vs GEM+TS-1 for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2007-06","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT01096745","phase":"PHASE2","title":"Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer","status":"TERMINATED","sponsor":"Gyeongsang National University Hospital","startDate":"2010-07","conditions":"Metastatic Biliary Tract Cancer, Locally Advanced Biliary Tract Cancer","enrollment":78},{"nctId":"NCT00209677","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer","status":"SUSPENDED","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2004-12","conditions":"Pancreatic Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Background Gemcitabine-based Chemotherapy Regimen","This regimen is not allowed for countries in the European Union.","gemzar","TS-1"],"phase":"phase_3","status":"active","brandName":"Gemcitabine + S-1","genericName":"Gemcitabine + S-1","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine and S-1 are cytotoxic chemotherapy agents that work synergistically to inhibit DNA synthesis and cell division in cancer cells. Used for Pancreatic cancer, Biliary tract cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}